Erina Koga‐Yamakawa

Author

Erina Koga‐Yamakawa

Sumitomo Dainippon Pharma (Japan)

Also Known As

E Koga-Yamakawa, E. Koga‐Yamakawa, Erina Koga-Yamakawa, Erina Koga‐Yamakawa

Publications

210

Citations

H-Index

Concepts

All Affiliations

Sumitomo Dainippon Pharma (Japan)AstraZeneca (United Kingdom)University of Manchester Boston Biomedical (United States)

About

Erina Koga‐Yamakawa is an author at Sumitomo Dainippon Pharma (Japan) specializing in medicine, immunology, and tumor immunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	77
2	Immunology	4	4	77
3	Natural Sciences	1	1	16
4	Allergy	1	1	10
5	Biology	1	1	16

Erina Koga‐Yamakawa

Publications

204

Citations

H-Index

Page 1

	Year	Citations
A novel systemically administered toll‐like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models Amy L. Adlard, Simon J. Dovedi, Brian A. Telfer, International Journal of Cancer	2014	50
Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy Simon J. Dovedi, Amy L. Adlard, Yosuke Ota, Oncotarget	2016	30
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies Alexander I. Spira, Aaron R. Hansen, Wael A. Harb, Targeted Oncology	2021	29
Intratracheal and oral administration of SM‐276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer Erina Koga‐Yamakawa, Simon J. Dovedi, Masashi Murata, International Journal of Cancer Topical Tlr7 AgonistsImmunologyImmunoeditingOral AdministrationImmunotherapeutics	2012	27
TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice Erina Koga‐Yamakawa, Masashi Murata, Simon J. Dovedi, Cancer Immunology Immunotherapy Tlr7 ToleranceCancer ImmunosurveillanceAutoimmune DiseaseT-regulatory CellImmunology	2015	24
DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects Yosuke Ota, Yasuhiro Nagai, Yuko Hirose, Frontiers in Immunology	2023	18
Arabino-mycolates derived from cell-wall skeleton of <i>Mycobacterium bovis</i> BCG as a prominent structure for recognition by host immunity Masanori Miyauchi, Masashi Murata, Keiko Shibuya, Drug Discoveries & Therapeutics Pathogenic MicrobiologyMicrobial PathogensBacteriologyImmune RegulationGlycobiology	2011	16
Abstract 4726: Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody Yosuke Ota, Takeshi Otsubo, Junya Koroki, Cancer Research Innate Immune SystemImmunologyImmune RegulationImmunologic MechanismCd4 T Cell Responses	2018	10

Page 1